Biomarker modeling of alzheimer's disease

Clifford R. Jack; David M. Holtzman

doi:10.1016/j.neuron.2013.12.003

Biomarker modeling of alzheimer's disease

Clifford R. Jack, David M. Holtzman

Radiology

Research output: Contribution to journal › Review article › peer-review

486 Scopus citations

Abstract

Alzheimer's disease (AD) is a slowly progressing disorder in which pathophysiological abnormalities, detectable invivo by biomarkers, precede overt clinical symptoms by many years to decades. Five AD biomarkers are sufficiently validated to have been incorporated into clinical diagnostic criteria and commonly used in therapeutic trials. Current AD biomarkers fall into two categories: biomarkers of amyloid-β plaques and of tau-related neurodegeneration. Three of the five are imaging measures and two are cerebrospinal fluid analytes. AD biomarkers do not evolve in an identical manner but rather in a sequential but temporally overlapping manner. Models of the temporal evolution of AD biomarkers can take the form of plots of biomarker severity (degree of abnormality) versus time. In this Review, we discuss several time-dependent models of AD that take into consideration varying age of onset (early versus late) and the influence of aging and co-occurring brain pathologies that commonly arise in the elderly.

Original language	English (US)
Pages (from-to)	1347-1358
Number of pages	12
Journal	Neuron
Volume	80
Issue number	6
DOIs	https://doi.org/10.1016/j.neuron.2013.12.003
State	Published - Dec 18 2013

ASJC Scopus subject areas

General Neuroscience

Access to Document

10.1016/j.neuron.2013.12.003

Cite this

@article{aa035436d175405dbb21aec6f055dd0c,

title = "Biomarker modeling of alzheimer's disease",

abstract = "Alzheimer's disease (AD) is a slowly progressing disorder in which pathophysiological abnormalities, detectable invivo by biomarkers, precede overt clinical symptoms by many years to decades. Five AD biomarkers are sufficiently validated to have been incorporated into clinical diagnostic criteria and commonly used in therapeutic trials. Current AD biomarkers fall into two categories: biomarkers of amyloid-β plaques and of tau-related neurodegeneration. Three of the five are imaging measures and two are cerebrospinal fluid analytes. AD biomarkers do not evolve in an identical manner but rather in a sequential but temporally overlapping manner. Models of the temporal evolution of AD biomarkers can take the form of plots of biomarker severity (degree of abnormality) versus time. In this Review, we discuss several time-dependent models of AD that take into consideration varying age of onset (early versus late) and the influence of aging and co-occurring brain pathologies that commonly arise in the elderly.",

author = "Jack, {Clifford R.} and Holtzman, {David M.}",

note = "Funding Information: C.R.J. was supported by NIH grants (R01 AG011378 and R01 AG041851) and the Alexander Family Professorship of Alzheimer{\textquoteright}s Disease Research. D.M.H. was supported by NIH grants (P50-AG05681, P01-AG03991, P01-26276). D.M.H. is a cofounder, on the scientific advisory board, and has ownership interests in C2N Diagnostics, LLC. He has consulted for AstraZeneca, Genentech, and Eli Lilly.",

year = "2013",

month = dec,

day = "18",

doi = "10.1016/j.neuron.2013.12.003",

language = "English (US)",

volume = "80",

pages = "1347--1358",

journal = "Neuron",

issn = "0896-6273",

publisher = "Cell Press",

number = "6",

}

TY - JOUR

T1 - Biomarker modeling of alzheimer's disease

AU - Jack, Clifford R.

AU - Holtzman, David M.

N1 - Funding Information: C.R.J. was supported by NIH grants (R01 AG011378 and R01 AG041851) and the Alexander Family Professorship of Alzheimer’s Disease Research. D.M.H. was supported by NIH grants (P50-AG05681, P01-AG03991, P01-26276). D.M.H. is a cofounder, on the scientific advisory board, and has ownership interests in C2N Diagnostics, LLC. He has consulted for AstraZeneca, Genentech, and Eli Lilly.

PY - 2013/12/18

Y1 - 2013/12/18

N2 - Alzheimer's disease (AD) is a slowly progressing disorder in which pathophysiological abnormalities, detectable invivo by biomarkers, precede overt clinical symptoms by many years to decades. Five AD biomarkers are sufficiently validated to have been incorporated into clinical diagnostic criteria and commonly used in therapeutic trials. Current AD biomarkers fall into two categories: biomarkers of amyloid-β plaques and of tau-related neurodegeneration. Three of the five are imaging measures and two are cerebrospinal fluid analytes. AD biomarkers do not evolve in an identical manner but rather in a sequential but temporally overlapping manner. Models of the temporal evolution of AD biomarkers can take the form of plots of biomarker severity (degree of abnormality) versus time. In this Review, we discuss several time-dependent models of AD that take into consideration varying age of onset (early versus late) and the influence of aging and co-occurring brain pathologies that commonly arise in the elderly.

AB - Alzheimer's disease (AD) is a slowly progressing disorder in which pathophysiological abnormalities, detectable invivo by biomarkers, precede overt clinical symptoms by many years to decades. Five AD biomarkers are sufficiently validated to have been incorporated into clinical diagnostic criteria and commonly used in therapeutic trials. Current AD biomarkers fall into two categories: biomarkers of amyloid-β plaques and of tau-related neurodegeneration. Three of the five are imaging measures and two are cerebrospinal fluid analytes. AD biomarkers do not evolve in an identical manner but rather in a sequential but temporally overlapping manner. Models of the temporal evolution of AD biomarkers can take the form of plots of biomarker severity (degree of abnormality) versus time. In this Review, we discuss several time-dependent models of AD that take into consideration varying age of onset (early versus late) and the influence of aging and co-occurring brain pathologies that commonly arise in the elderly.

UR - http://www.scopus.com/inward/record.url?scp=84890528022&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890528022&partnerID=8YFLogxK

U2 - 10.1016/j.neuron.2013.12.003

DO - 10.1016/j.neuron.2013.12.003

M3 - Review article

AN - SCOPUS:84890528022

SN - 0896-6273

VL - 80

SP - 1347

EP - 1358

JO - Neuron

JF - Neuron

IS - 6

ER -

Biomarker modeling of alzheimer's disease

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this